0000000000411308

AUTHOR

Francesca Provenzano

showing 3 related works from this author

Nuove stazioni in Sicilia di Petalophyllum ralfsii (Hepatophyta), specie minacciata in Europa, e di altre briofite rare in Italia meridionale

2011

Petalophyllum briofite rare ItaliaLife Sciences
researchProduct

Efficacy and Renal Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus Also Receiving Metformin: A Real-Life Experience.

2017

Introduction. This study aimed at evaluating the efficacy and safety of dapagliflozin in patients with type 2 diabetes (T2D) who also received metformin in clinical practice in Italy. Methods. This was a retrospective observational study and it included data from patients who received dapagliflozin 10 mg once daily in conjunction with metformin for 12 months (DAPA + MET). In those with inadequate glycemic control, insulin or glimepiride was added after 30 days (DAPA + MET + other glucose-lowering drugs). Efficacy assessments included glycosylated hemoglobin (HbA1c) levels at 6 and 12 months, as well as body mass index (BMI) and lipid parameters at 12 months. Safety was also assessed. Result…

Blood GlucoseMalemedicine.medical_specialtyArticle Subjectendocrine system diseasesEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismType 2 diabeteslcsh:Diseases of the endocrine glands. Clinical endocrinologyBody Mass Index03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyGlucosidesInternal medicineDiabetes mellitusmedicineHumansHypoglycemic Agents030212 general & internal medicineDapagliflozinBenzhydryl CompoundsAgedRetrospective StudiesGlycated Hemoglobinlcsh:RC648-665business.industryType 2 Diabetes Mellitusnutritional and metabolic diseasesRetrospective cohort studyMiddle Agedmedicine.diseaseMetforminMetforminTreatment OutcomechemistryDiabetes Mellitus Type 2Observational studyDrug Therapy CombinationFemalebusinessBody mass indexmedicine.drugResearch ArticleJournal of diabetes research
researchProduct

Exenatide once-weekly improves metabolic parameters, endothelial dysfunction and carotid intima-media thickness in patients with type-2 diabetes: An …

2019

AIM: To evaluate the effect of exenatide long acting release (LAR) on carotid intima-media thickness (IMT) and endothelial function in patients with type 2 diabetes mellitus. METHODS: Sixty subjects with type 2 diabetes mellitus were treated with exenatide LAR as add-on to stable doses of metformin for 8 months in an open label study. Anthropometric variables, lipid profile and glycemic parameters were assessed by routine analysis. Carotid IMT by Doppler ultrasound and endothelial function by flow-mediated dilation of the brachial artery were also assessed. RESULTS: Exenatide significantly improved fasting glycaemia (from 8.8 ± 2.8 to 7.3 ± 2.2 mmol/L, p < 0.0001), HbA1c (from 8.0 ± 0.4 …

Malemedicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismType 2 diabetesCarotid Intima-Media ThicknessCarotid intima-media thickne03 medical and health sciences0302 clinical medicineEndocrinologyRisk FactorsInternal medicineDiabetes mellitusInternal MedicineMedicineHumansHypoglycemic Agentscardiovascular diseases030212 general & internal medicineProspective StudiesEndothelial dysfunctionmedicine.diagnostic_testbusiness.industryType 2 Diabetes MellitusGeneral MedicineMiddle Agedmedicine.diseaseCardiovascular diseaseAtherosclerosisMetforminIntima-media thicknessDiabetes Mellitus Type 2Atherosclerosicardiovascular systemCardiologyExenatideFemalebusinessLipid profileExenatidemedicine.drugDiabetes research and clinical practice
researchProduct